To recapitulate α-synuclein–associated lipid oxidative stress in vivo, the ferroptosis inducer sorafenib was administered at a low dosage, around 6 months before the expected onset of overt parkinsonism (Figure 3A). Here, SNCA is linked to Parkinson disease.